american thyroid association hyperthyroidism guidelines-rebecca經(jīng)典培訓(xùn)課件_第1頁(yè)
american thyroid association hyperthyroidism guidelines-rebecca經(jīng)典培訓(xùn)課件_第2頁(yè)
american thyroid association hyperthyroidism guidelines-rebecca經(jīng)典培訓(xùn)課件_第3頁(yè)
american thyroid association hyperthyroidism guidelines-rebecca經(jīng)典培訓(xùn)課件_第4頁(yè)
american thyroid association hyperthyroidism guidelines-rebecca經(jīng)典培訓(xùn)課件_第5頁(yè)
已閱讀5頁(yè)，還剩30頁(yè)未讀， 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明：本文檔由用戶(hù)提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

2021AmericanThyroidAssociationHyperthyroidismGuidelines:

What’sNew?MerckThyr0idSymposiumApril22-23,2021Dalian,ChinaRebeccaBahnMDProfessorofMedicineMayoCliniccollegeofMedicineRochester,MNThyroid:21,593;2021Thyroid:25,1343;2021What’snewintheguidelines?ExpandeduseofTRAbmeasurementsInformationconcerningATDhepatotoxicityandsafetyoflong-termuseModifiedmanagementofGDbeforeandduringpregnancyOptimizationofcalciumandvitaminDmetabolismpriortothyroidectomyStillatthecoreofoptimummanagement:

Patient-centricdecisionmaking“Oncethediagnosishasbeenmade,thetreatingphysicianandpatientshoulddiscusseachofthetreatmentoptions,includingthelogistics,benefits,expectedspeedofrecovery,drawbacks,potentialsideeffectsandcost.Thissetsthestageforthephysiciantomakerecommendationsbasedonbestclinicaljudgmentandallowsthefinaldecisiontoincorporatethepersonalvaluesandpreferencesofthepatient.〞AdvantagesDisadvantagesAntithyroiddrugs

avoidlife-longLT4replacementavoidradiationexposureavoidrisksofsurgerypossibledrugreactionnotdefinitivetherapyRadioiodinedefinitivetherapyavoidrisksofsurgeryavoidadversedrugreactionradiationexposurelife-longLT4replacementpossibleGOworseningThyroidectomyrapidresolutionavoidradiationexposureavoidadversedrugreactionpossibleGOimprovementsurgicalrisk(hypoparathyroidism,recurrentlaryngealnervedamage)life-longLT4replacementAdvantagesandDisadvantagesofTreatmentoptionsforGDBahnetal.Thyroid:21,593;2021ToolforSharedDecisionMakingAbouttheTreatmentofGraves'Disease.BritoJPetal.Thyroid25(11):1191,2021UseofTRAbmeasurementsin:DiagnosisofGDDiscontinuingATDtherapyAssessingriskoffetal/neonatalGD2021:AradioactiveiodineuptakeshouldbeperformedwhentheclinicalpresentationofthyrotoxicosisisnotdiagnosticofGraves’disease.Athyroidscanshouldbeaddedinthepresenceofthyroidnodularity.2021:Ifthediagnosisisnotapparentbasedontheclinicalpresentationandinitialbiochemicalevaluation,diagnostictestingisindicatedandcaninclude,dependingonavailableexpertiseandresources,(1)measurementofTRAb,(2)determinationoftheradioactiveiodineuptake,or(3)measurementofthyroidalbloodflowonultrasonography.123Ior99mTcpertechnetatescanshouldbeobtainedwhentheclinicalpresentationsuggeststoxicadenomaortoxicmultinodulargoiter.TSIAssayUtilization:ImpactonCostsofGraves’

HyperthyroidismDiagnosis

McKeeA,PeyerlF.AmJManagedCare.2021;18(1):e1-e14Anevidence-basedeconomicmodelwasdevelopedinapopulationof100,000managedcareenrollees.InclusionofaTSItestearlyinthediagnosticpathwayresultedin:Netdirectcostsofdiagnosisreducedby43%.Netcostofavoidingmisdiagnosisandtreatmentofunexplainedsymptomsreducedby85%.Overallnetcostandtimetodiagnosiswerebothreducedby50%TheuseofcolordopplerUStomeasurethyroidbloodflowanddifferentiateGDfrompainlessthyroiditis

HiraiwaT,etal.EurThyroidJ2021;2:2120Superiorthyroidarterybloodflowvelocitysensitivity=0.87specificity=1.00.Thyroidtissuebloodflowsensitivity=0.71specificity=1.00.UseofTRAbindecisiontodiscontinueATDtherapy 2021IfmethimazoleischosenastheprimarytherapyforGD,themedicationshouldbecontinuedforapproximately12–18months,thentaperedordiscontinuediftheTSHisnormalatthattime.MeasurementofTRAblevelspriortostoppinganti-thyroiddrugtherapyissuggested…..2021IfMMIischosenastheprimarytherapyforGD,themedicationshouldbecontinuedforapproximately12–18months,thendiscontinuediftheTSHandTRAblevelsarenormalatthattime.TRAbpositiveafter18monthsMMIRx=89%relapserateTRAbnegativeafter18mosMMIRx=29%relapserateLaurbergPetal.EurJEndocrinol2021;158:69-752021:PatientsfoundtohaveGDduringpregnancy(orwhoweretreatedwithRAIorthyroidectomyforGDpriortopregnancy)shouldhaveTRAblevelsmeasuredatdiagnosisusingasensitiveassayand,ifelevated,againat22–26weeksofgestation.

2021:PatientsreceivingATDforGDwhenbecomingpregnant(orwhoweretreatedwithRAIorthyroidectomyforGDpriortopregnancy)orfoundtohaveGDduringpregnancyshouldhaveTRAblevelsmeasuredatinitialpregnancyvisitoratdiagnosisusingasensitiveassayand,iftheyareelevated,againat18–22weeksofgestation.UseofTRAbinassessingriskoffetal/neonatalGD

EarlySevereFetalGravesDiseaseinaMotherafterThyroidAblationandThyroidectomy

DonnellyMAetal.ObstetGynecol2021;125:1059–6236-year-oldwomanwithhistoryofsevereGD,radioiodineablationandthyroidectomyUSat18weeksshowedfetustobeseverelytachycardicwithagoiter.MaternalTSIandTRAbwere“toohightomeasure〞P.H.BisschopPH,vanTrotsenburgASP.NEJM370;13,2021NewinformationconcerningATDhepatotoxicity2021:LiverfunctionandhepatocellularintegrityshouldbeassessedinpatientstakingMMIorPTUwhoexperiencepruriticrash,jaundice,light-coloredstoolordarkurine,jointpain,abdominalpainorbloating,anorexia,nausea,orfatigue.2021:LiverfunctionandhepatocellularintegrityshouldbeassessedinpatientstakingPTUwhoexperiencepruriticrash,jaundice,light-coloredstoolordarkurine,jointpain,abdominalpainorbloating,anorexia,nausea,orfatigue.Antithyroiddrug‐relatedhepatotoxicityinhyperthyroidpatients:

apopulation‐basedcohortstudy

WangM-T,LeeW-J,HuangT-Y,ChuC-L,Hsieh,C-H.BJClinPharm78:(3)619-629,202171,379newusersofATDslistedinTaiwanNationalHealthInsuranceDatabaseMMIwasassociatedwithasignificantlyhigherrateofnoninfectioushepatitisthanPTU(0.25%vs.0.08%)PTUwasassociatedwithasignificantlyhigherrateofacuteliverfailurethanMMI(0.048%vs.0.026%)Nodifferenceonrateofcholestasis(0.019%vs.0.016%)Antithyroiddrug‐relatedhepatotoxicityinhyperthyroidpatients:

apopulation‐basedcohortstudy

WangM-T,LeeW-J,HuangT-Y,ChuC-L,Hsieh,C-H.BJClinPharm78:3,619-629

highdosePTUhazardratioSafetyoflong-termATDuse2021and2021:IfapatientwithGDbecomeshyperthyroidaftercompletingacourseofMMI,considerationshouldbegiventotreatmentwithRAIorthyroidectomy.Continuedlow-doseMMItreatmentforlongerthan12–18monthsmaybeconsideredinpatientsnotinremissionwhopreferthisapproach.However,newdatasupportsafetyoflong-termATDuseAntithyroidDrugSideEffectsinthePopulation

AndersenSL,OlsenJ,LaurbergP.JClinEndocrinolMetab2021;101(4):1606-1614.Durationoftreatmentuptotheevent(days)28,998patients:Most(83%)developedthesideeffectwithin3monthsofATDinitiationorre-initiationafterrelapseAnalysisof90casesofATD-inducedseverehepatotoxicityover13yearsinChina

YangJetal.Thyroid25(3);278,2021Hepatotoxicityoccurredwithin12weeksofstartingATDtherapyin80%ofpatients.SeverehepatotoxicitydidnotdifferbetweenMMIandPTU(p=0.188).Frequencyofcholestatichepatotoxicitydidnotdiffer(p=0.069).Analysisof754CasesofAntithyroidDrug-InducedAgranulocytosisOver30YearsinJapan

NakamuraH,etal.ClinEndocrinolMetab98:4776–4783,2021ModifiedmanagementofGDbeforeandduringpregnancy2021:WomenwithGDthatiswellcontrolledonMMIandwhodesirepregnancyhaveseveraloptions:Patientscouldconsiderde?nitivetherapybeforetheybecomepregnant.PatientscouldswitchtoPTUbeforetryingtoconceive.PatientscouldswitchtoPTUassoonaspregnancyisdiagnosed.AppropriatelyselectedpatientscouldwithdrawfromATDtherapyassoonaspregnancyisdiagnosed.IfATDtherapyiswithdrawn,thyroidfunctionshouldbeassessedweeklythroughoutthe?rsttrimester,thenmonthly.2021:WesuggestthatpatientstakingMMIwhodecidetobecomepregnantobtainpregnancytestingattheearliestsuggestionofpregnancyandbeswitchedtoPTUassoonaspossibleinthefirsttrimester.2021:WomentakingPTUduringthe?rsttrimesterofpregnancymaybeswitchedtoMMIatthebeginningofthesecondtrimester,ortheymaycontinuePTUtherapyfortheremainingpartofpregnancyifATDisneeded.Norecommendation;insuf?cientevidencetoassessbene?tsandrisks.2021:WesuggestthatwomentakingPTUduringthe?rsttrimesterofpregnancybechangedbacktoMMIatthebeginningofthesecondtrimester.Similarly,wesuggestthatpatientsstartedonPTUduringthefirsttrimesterbeswitchedtoMMIatthebeginningofthesecondtrimester.Weakrecommendation;poorqualityevidence BirthDefectsAfterEarlyPregnancyUseofAntithyroidDrugs:ADanishNationwideStudyAndersenS,OlsenJ,WuHenSen,LaurbergP.JClinEndocrinolMetab98:4373,2021BothMMI/CMZwereassociatedwithbirthdefects,butthespectrumofmalformationsdiffered.Prevalenceofbirthdefectswashigh:PTU=8.0%;OR=1.03MMI/CMZ=9.1%;OR=1.66PTU+MMI/CMZ=10.1%;OR=1.82Notexposed=5.7%OptimizationofcalciumandvitaminDmetabolismpriortothyroidectomyNewin2021Calciumand25-hydroxyvitaminDshouldbeassessedpreoperativelyandrepletedifnecessary,orgivenprophylactically.Calcitriolsupplementationshouldbeconsideredpreoperativelyinpatientsatincreasedriskfortransientorpermanenthypoparathyroidism.Preventingpostoperativehypocalcemia

inpatientswithGraves’disease

OltmannSCetal.2021AnnSurgOncol22:952–958GDpatients(n=45)given1.0gofcalciumcarbonate(CC)threetimesadayfor2weeksbeforetotalthyroidectomy(TT);HistoriccontrolswithGD(n=38)orotherindicationforTT(n=40)PostoperativecalciumlevelsGDw/oCCpre-treatment(8.3mg/dL)vs.GDwithCCorControlw/oGDorCC(both8.6mg/dL;p=0.05)PostoperativenumbnessandtinglingGDw/oCC(26%)vs.GDwithCC(9%)orControlw/oGDorCC(10%;p<0.05)Meta-analysisofpredictorsofpost

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽，若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間，僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請(qǐng)與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論